FDA Approves First Gene Therapy for Inherited Hearing Loss

In late April 2026, the US Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), the first gene therapy ever cleared to treat a genetic form of hearing loss. Developed by Regeneron, it is for patients with severe-to-profound hearing loss caused by confirmed variants in both copies of the OTOF gene, which the body needs to produce otoferlin, a protein that helps relay sound from the inner ear to the auditory nerve.

The therapy is given as a one-time surgical infusion into the cochlea, using a dual adeno-associated virus system to deliver a working copy of the OTOF gene. Once in place, the inner ear can begin making its own otoferlin, effectively reconnecting the circuit between the ear and the nerve. It is a strikingly different approach from hearing aids or cochlear implants, which manage the problem rather than addressing its genetic root.

“Developed by Regeneron, it is for patients with severe-to-profound hearing loss caused by confirmed variants in both copies of the OTOF gene, which the body needs to produce otoferlin, a protein that helps relay sound from the inner ear to the auditory nerve.”

The approval was based on the CHORD trial of 20 participants. Sixteen of them — 80% — met the primary endpoint of improved hearing, and follow-up data pointed to a durable effect. OTOF-related deafness is very rare, affecting only about 50 infants born in the US each year, and Regeneron announced it will provide Otarmeni free of charge to eligible US patients, removing the cost barrier for the small group who can benefit.

There are important limits to keep in mind. Otarmeni works only for hearing loss caused by OTOF variants, a small slice of all genetic deafness, and it does not help the far larger number of people whose hearing loss has other causes. As an accelerated approval, it will need continued study to confirm long-term benefit. Even so, for children who might otherwise grow up unable to hear, a one-time therapy that can restore hearing is a profound milestone — and a sign of how gene therapy is beginning to reach conditions once thought permanent.